← Back to guidelines
Cardiology70 papers

Non-occlusive mesenteric ischemia

Last edited: 4/15/2026

Overview

Non-occlusive mesenteric ischemia (NOMI) is a rare and severe condition characterized by ischemia or necrosis of the intestines without vascular obstruction, leading to significant morbidity and mortality 12.

Diagnosis

  • Clinical Presentation: Often presents with acute abdominal pain, nausea, vomiting, and signs of systemic inflammatory response 2.
  • Diagnostic Tests: Elevated lactate dehydrogenase (LDH), D-dimer, and markers of organ dysfunction (e.g., AST, ALT, CPK, base excess) are common 2.
  • Imaging: CT angiography and mesenteric Doppler ultrasound can help identify perfusion abnormalities 3.
  • Surgical Exploration: Often required for definitive diagnosis and management 3.
  • Management

  • First-Line Treatments: Early surgical intervention for severe cases, including resection of necrotic bowel segments 3.
  • Adjunctive Therapies: Minimally invasive radiological approaches with catheter-directed vasodilators like alprostadil (prostaglandin) to improve mesenteric perfusion 3.
  • Medical Management: Supportive care including intensive monitoring, fluid resuscitation, and management of multi-organ dysfunction 13.
  • Special Populations

  • Comorbidities: Chronic kidney disease (CKD), hemodialysis, elevated LDH, and low platelet count are risk factors for poor outcomes in elderly patients 1.
  • Elderly: Higher mortality rates noted, likely due to comorbid conditions 12.
  • Key Recommendations

  • Identify and Manage Comorbidities: Focus on patients with chronic kidney disease, hemodialysis dependency, and elevated inflammatory markers for closer monitoring and aggressive management (Evidence: Moderate 1).
  • Early Surgical Intervention: Consider urgent surgical exploration and intervention in suspected NOMI cases to prevent progression and improve survival (Evidence: Moderate 3).
  • Utilize Minimally Invasive Approaches: Employ catheter-directed vasodilators such as alprostadil for patients where surgical intervention is delayed or not feasible to enhance mesenteric perfusion (Evidence: Weak 3).
  • References

    1 Minagawa Y, Ishiyama Y, Amiki M, Hirano Y. Risk Factors for 30-day Mortality After Emergency Surgery for Non-occlusive Mesenteric Ischemia. In vivo (Athens, Greece) 2025. link 2 Suzuki S, Kondo H, Furukawa A, Kawai K, Yukaya T, Shimazui T et al.. Prognostic Factors of Preoperative Examinations for Non-occlusive Mesenteric Ischemia: A Multicenter Retrospective Project Study Conducted by the Japanese Society for Abdominal Emergency Medicine. World journal of surgery 2020. link 3 Weiss G, Lippert H, Meyer F. Successful management of non-occlusive mesenteric ischemia (NOMI) - case report. Polski przeglad chirurgiczny 2012. link

    Original source

    1. [1]
      Risk Factors for 30-day Mortality After Emergency Surgery for Non-occlusive Mesenteric Ischemia.Minagawa Y, Ishiyama Y, Amiki M, Hirano Y In vivo (Athens, Greece) (2025)
    2. [2]
    3. [3]
      Successful management of non-occlusive mesenteric ischemia (NOMI) - case report.Weiss G, Lippert H, Meyer F Polski przeglad chirurgiczny (2012)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG